Results of new psychedelic research aimed at patients with severe treatment resistant depression (TRD) found significant decreases in their depressive symptoms. Researchers of the open-label study also found significant safety and efficacy of synthetic psilocybin in TRD patients.
This Comment explores the legal, ethical, and regulatory challenges surrounding the use of psilocybin-assisted psychotherapy for terminally ill patients under the federal Right to Try (RTT) Act. While psychedelics like psilocybin are demonstrating extraordinary therapeutic potential, particularly in easing end-of-life psychological distress, patients remain ...
This scoping review examines the emerging evidence for psilocybin-assisted therapy (PAP) in treating trauma-related disorders such as posttraumatic stress disorder (PTSD), depression, and persistent post-concussion symptoms (PPCS), with specific implications for intimate partner violence (IPV)-related brain injury and PTSD. Guided by PRISMA-ScR methodology, ...
Although psychedelics were banned from medical research for about fifty years, recent early-phase studies indicate they may offer unique therapeutic benefits for various mental health and substance use disorders. When effective, psychedelic experiences often involve phenomena not typically observed in other medical or psychiatric interventions, such as a dim...
The goal of this clinical trial is to learn if PEX010 is effective for the treatment of Stimulant Use Disorder in adults. The study will also assess the safety and feasibility of administering PEX010 to this population. The main questions it aims to answer are: Does PEX010 reduce stimulant use? What medical problems do participants experience when taking PEX...
This study is an open-label, single-arm, proof-of-concept study, wherein treatment resistant bipolar depression (TRBD) participants will receive one 25 mg dose of oral psilocybin accompanied by preparatory, monitoring, and integration psychotherapy sessions (psilocybin-assisted psychotherapy, or PAP). Using fMRI (functional magnetic resonance imaging), the f...
There is some evidence that the subjective effects of ketamine and other psychedelics like psilocybin are crucial for their therapeutic outcomes, such as treatment of depression or substance use disorder (SUD). We performed a meta-analysis and systematic review on the correlation of subjective symptoms and dissociation versus ketamine-induced therapeutic out...
Artificial intelligence (AI) and psychedelic medicines are among the most high-profile evolving disruptive innovations within mental healthcare in recent years. Although AI and psychedelics may not have historically shared any common ground, there exists the potential for these subjects to combine in generating innovative mental health treatment approaches. ...
Title: Use of psilocybin in the treatment of mental disorders: systematic review of clinical trials. Objective: To evaluate the high-impact evidence on the neurobiology, efficacy, safety, and feasibility of using psilocybin in the treatment of mental disorders such as depression, anxiety, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (P...
Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential...
This work utilized fMRI to assess the influence of the psychedelics, Psilocybin, a serotonergic agonist, and Salvinorin-A, a kappa-opioid receptor (KOR) agonist, on functional connectivity (FC) in non-human primates. We used a seed-based FC analysis, probing regions of interest associated with psychedelic hallucinogens. Our findings highlight the overlapping...
Background: Research investigating high-dose, high-support psilocybin-assisted therapy reports significant psychological benefits, increased consciousness, and an enhanced socio-cognitive niche, resulting in empathy, connection, creativity, and overall well-being. These qualities lend themselves well to the bonding, emotional regulation, and attachment requi...
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.
Abstract Effective interventions for neuropsychiatric disorders may work by rebalancing the brain’s functional hierarchical organization. Here we directly investigated the effects of two different serotonergic pharmacological interventions on functional brain hierarchy in major depressive disorder in a two-arm double-blind phase II randomized controlled tria...
Many medicines and treatments for varying levels of ailments were found through natural bioactives before complex separation techniques were available.Ironically, as medicine advances, drastically more people seem to be reverting to a desire for these natural bioactives.Due to this, it is important to discover and research the pharmacology of historically us...
Introduction: Mental disorders are common and still growing problem around the globe. Significantly decreasing quality of life, they are often source of true suffering for patients and their families leading to further health issues or even dramatic outcomes resulting in death. As public awareness rises, more and more people understand risks and tend to look...
